1
|
Wang W, Zhang Z, Zhang X, Yu H, Luo H, Huo D, Xu Y, Zhao X. Synthesis of Polysubstituted 2,3-Dihydropyridin-4(1 H)-one in Water. CHINESE J ORG CHEM 2023. [DOI: 10.6023/cjoc202207032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2023]
|
2
|
Qin Z, Ou S, Xu L, Sorensen K, Zhang Y, Hu DP, Yang Z, Hu WY, Chen F, Prins GS. Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-Deficient prostate cancer cells. Chem Biol Drug Des 2021; 97:1059-1078. [PMID: 33470049 PMCID: PMC8168342 DOI: 10.1111/cbdd.13826] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Revised: 12/16/2020] [Accepted: 01/10/2021] [Indexed: 12/16/2022]
Abstract
Sustained androgen receptor (AR) signaling and apoptosis evasion are among the main hurdles of castration-resistant prostate cancer (CRPC) treatment. We designed and synthesized isothiocyanate (ITC)-containing hybrid AR antagonist (ITC-ARi) and rationally combined ITC-ARi with GSH synthesis inhibitor buthionine sulfoximine (BSO) to efficiently downregulate AR/AR splice variant and induce ferroptosis in CRPC cells. The representative ITC-ARi 13 is an AR ligand that contains an N-acetyl cysteine-masked ITC moiety and gradually releases parental unconjugated ITC 12b in aqueous solution. The in vitro anti-PCa activities of 13, such as growth inhibition and AR downregulation, are significantly enhanced when combined with BSO. The drug combination caused notable lipid peroxidation and the cell viability was effectively rescued by iron chelator, antioxidants or the inhibitor of heme oxygenase-1, supporting the induction of ferroptosis. 13 and BSO cooperatively downregulate AR and induce ferroptosis likely through increasing the accessibility of 13/12b to cellular targets, escalating free intracellular ferrous iron and attenuating GSH-centered cellular defense and adaptation. Further studies on the combination of ITC-ARi and GSH synthesis inhibitor could result in a new modality against CRPC.
Collapse
Affiliation(s)
- Zhihui Qin
- Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA
| | - Siyu Ou
- Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA
| | - Liping Xu
- Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA
| | - Kathleen Sorensen
- Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA
| | - Yingxue Zhang
- Department of Biochemistry, Microbiology and Immunology, Wayne State University School of Medicine, Detroit, MI, USA
| | - Dan-Ping Hu
- Department of Urology, University of Illinois at Chicago, Chicago, IL, USA
| | - Zhe Yang
- Department of Biochemistry, Microbiology and Immunology, Wayne State University School of Medicine, Detroit, MI, USA
| | - Wen-Yang Hu
- Department of Urology, University of Illinois at Chicago, Chicago, IL, USA
| | - Fei Chen
- Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA
| | - Gail S. Prins
- Department of Urology, University of Illinois at Chicago, Chicago, IL, USA
| |
Collapse
|
3
|
Taylor CJ, Alter A, Pask CM, Sridharan V. Imino Diels-Alder/transition metal catalyzed reactions to synthesise fused ring heterocycles. J Organomet Chem 2020. [DOI: 10.1016/j.jorganchem.2020.121197] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
4
|
Arjun HA, Elancheran R, Manikandan N, Lakshmithendral K, Ramanathan M, Bhattacharjee A, Lokanath NK, Kabilan S. Design, Synthesis, and Biological Evaluation of (E)-N'-((1-Chloro-3,4-Dihydronaphthalen-2-yl)Methylene)Benzohydrazide Derivatives as Anti-prostate Cancer Agents. Front Chem 2019; 7:474. [PMID: 31355179 PMCID: PMC6636335 DOI: 10.3389/fchem.2019.00474] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2019] [Accepted: 06/20/2019] [Indexed: 01/09/2023] Open
Abstract
Prostate Cancer (PCa) is the most frequently diagnosed cancer in men in their late '50s. PCa growth is mainly due to the activation of the androgen receptor by androgens. The treatment for PCa may involve surgery, hormonal therapy, and oral chemotherapeutic drugs. A structural based molecular docking approach revealed the findings of (E)-N'-((1-chloro-3,4-dihydronaphthalen-2-yl)methylene)benzohydrazide derivatives, where the possible binding modes of the compounds with protein (PDB ID: 3V49) are shown. The compounds (6a-k) were synthesized and characterized by using conventional methods. The compounds, 6g, 6j, and 6k were reconfirmed through single crystal X-ray diffraction (XRD). Further, the compounds (6a-k) and standard drug were evaluated against human prostate cancer cell lines, LNCaP and PC-3 and the non-cancerous cell line, 3T3. Among these compounds, 6g and 6j showed higher cytotoxicity, and 6g exhibited dose-dependent activity and reduced cell viability. The mechanism of action was observed through the induced apoptosis and was further confirmed by western blot and ELISA. Molecular dynamics simulation studies were carried out to calculate the interaction and the stability of the protein-ligand complex in motion. ADME properties were predicted for all the tested compounds. These findings may give vital information for further development.
Collapse
Affiliation(s)
- H. A. Arjun
- Drug Discovery Lab, Department of Chemistry, Annamalai University, Chidambaram, India
| | | | - N. Manikandan
- Department of Pharmacology, PSG College of Pharmacy, Coimbatore, India
| | - K. Lakshmithendral
- Drug Discovery Lab, Department of Chemistry, Annamalai University, Chidambaram, India
| | | | - Atanu Bhattacharjee
- Computational Biology Laboratory, Department of Biotechnology & Bioinformatics, North Eastern Hill University, Shillong, India
| | - N. K. Lokanath
- Department of Physics, University of Mysore, Mysore, India
| | | |
Collapse
|
5
|
Hu WY, Xu L, Chen B, Ou S, Muzzarelli KM, Hu DP, Li Y, Yang Z, Vander Griend DJ, Prins GS, Qin Z. Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75. Prostate 2019; 79:1166-1179. [PMID: 31135075 DOI: 10.1002/pros.23832] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2018] [Accepted: 04/29/2019] [Indexed: 12/14/2022]
Abstract
BACKGROUND The progression of castration-resistant prostate cancer (CRPC) still relies on the function of androgen receptor (AR), achieved by evolving mechanisms to reactivate AR signaling under hormonal therapy. Histone deacetylase inhibitors (HDACis) disrupt cytoplasmic AR chaperone heat shock protein 90 (Hsp90) via HDAC6 inhibition, leading to AR degradation and growth suppression of prostate cancer (PCa) cells. However, current HDACis are not effective in clinical trials treating CRPC. METHODS We designed hybrid molecules containing partial chemical scaffolds of AR antagonist enzalutamide (Enz) and HDACi suberoylanilide hydroxamic acid (SAHA) as new anti-PCa agents. We previously demonstrated that Enz-HDACi hybrid drug 2-75 targets both AR and Hsp90, which inhibits the growth of Enz-resistant C4-2 cells. In the current study, we further investigate the molecular and cellular actions of 2-75 and test its anti-PCa effects in vivo. RESULTS Compared with Enz, 2-75 had greater AR antagonistic effects by decreasing the stability, transcriptional activity, and nuclear translocation of intracellular AR. In addition to inhibition of full-length AR (FL AR), 2-75 downregulated the AR-V7 variant in multiple PCa cell lines. Mechanistic studies indicated that the AR affinity of 2-75 retains the drug in the cytoplasm of AR + PCa cells and further directs 2-75 to the AR-associated protein complex, which permits localized effects on AR-associated Hsp90. Further, unlike pan-HDACi SAHA, the cytoplasm-retaining property allows 2-75 to significantly inhibit cytoplasmic HDAC6 with limited impact on nuclear HDACs. These selective cytoplasmic actions of 2-75 overcome the unfavorable resistance and toxicity properties associated with classical AR antagonists, HDACis, and Hsp90 inhibitors. Finally, 2-75 showed greater antitumor activities than Enz in vivo on SQ xenografts derived from LNCaP cells. CONCLUSIONS Novel therapeutic strategy using newly designed 2-75 and related AR antagonist-HDACi hybrid drugs has great potential for effective treatment of CRPC.
Collapse
Affiliation(s)
- Wen-Yang Hu
- Department of Urology, University of Illinois at Chicago, Chicago, Illinois
| | - Liping Xu
- Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan
| | - Bailing Chen
- Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan
| | - Siyu Ou
- Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan
| | - Kendall M Muzzarelli
- Department of Biochemistry and Molecular Biology, Wayne State University School of Medicine, Detroit, Michigan
| | - Dan-Ping Hu
- Department of Urology, University of Illinois at Chicago, Chicago, Illinois
| | - Ye Li
- Department of Urology, University of Illinois at Chicago, Chicago, Illinois
| | - Zhe Yang
- Department of Biochemistry and Molecular Biology, Wayne State University School of Medicine, Detroit, Michigan
| | | | - Gail S Prins
- Department of Urology, University of Illinois at Chicago, Chicago, Illinois
| | - Zhihui Qin
- Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan
| |
Collapse
|
6
|
Moses MA, Kim YS, Rivera-Marquez GM, Oshima N, Watson MJ, Beebe KE, Wells C, Lee S, Zuehlke AD, Shao H, Bingman WE, Kumar V, Malhotra SV, Weigel NL, Gestwicki JE, Trepel JB, Neckers LM. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. Cancer Res 2018; 78:4022-4035. [PMID: 29764864 DOI: 10.1158/0008-5472.can-17-3728] [Citation(s) in RCA: 89] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Revised: 04/12/2018] [Accepted: 05/11/2018] [Indexed: 01/01/2023]
Abstract
Castration-resistant prostate cancer (CRPC) is characterized by reactivation of androgen receptor (AR) signaling, in part by elevated expression of AR splice variants (ARv) including ARv7, a constitutively active, ligand binding domain (LBD)-deficient variant whose expression has been correlated with therapeutic resistance and poor prognosis. In a screen to identify small-molecule dual inhibitors of both androgen-dependent and androgen-independent AR gene signatures, we identified the chalcone C86. Binding studies using purified proteins and CRPC cell lysates revealed C86 to interact with Hsp40. Pull-down studies using biotinylated-C86 found Hsp40 present in a multiprotein complex with full-length (FL-) AR, ARv7, and Hsp70 in CRPC cells. Treatment of CRPC cells with C86 or the allosteric Hsp70 inhibitor JG98 resulted in rapid protein destabilization of both FL-AR and ARv, including ARv7, concomitant with reduced FL-AR- and ARv7-mediated transcriptional activity. The glucocorticoid receptor, whose elevated expression in a subset of CRPC also leads to androgen-independent AR target gene transcription, was also destabilized by inhibition of Hsp40 or Hsp70. In vivo, Hsp40 or Hsp70 inhibition demonstrated single-agent and combinatorial activity in a 22Rv1 CRPC xenograft model. These data reveal that, in addition to recognized roles of Hsp40 and Hsp70 in FL-AR LBD remodeling, ARv lacking the LBD remain dependent on molecular chaperones for stability and function. Our findings highlight the feasibility and potential benefit of targeting the Hsp40/Hsp70 chaperone axis to treat prostate cancer that has become resistant to standard antiandrogen therapy.Significance: These findings highlight the feasibility of targeting the Hsp40/Hsp70 chaperone axis to treat CRPC that has become resistant to standard antiandrogen therapy. Cancer Res; 78(14); 4022-35. ©2018 AACR.
Collapse
Affiliation(s)
- Michael A Moses
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
| | - Yeong Sang Kim
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
| | - Genesis M Rivera-Marquez
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
| | - Nobu Oshima
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
| | - Matthew J Watson
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
| | - Kristin E Beebe
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
| | - Catherine Wells
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
| | - Sunmin Lee
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
| | - Abbey D Zuehlke
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
| | - Hao Shao
- Department of Pharmaceutical Chemistry and the Institute for Neurodegenerative Disease, University of California at San Francisco, San Francisco, California
| | - William E Bingman
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas
| | - Vineet Kumar
- Department of Radiation Oncology, Division of Radiation and Cancer Biology, Stanford University School of Medicine, Stanford, California
| | - Sanjay V Malhotra
- Department of Radiation Oncology, Division of Radiation and Cancer Biology, Stanford University School of Medicine, Stanford, California
| | - Nancy L Weigel
- Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas
| | - Jason E Gestwicki
- Department of Pharmaceutical Chemistry and the Institute for Neurodegenerative Disease, University of California at San Francisco, San Francisco, California
| | - Jane B Trepel
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland
| | - Leonard M Neckers
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland.
| |
Collapse
|
7
|
Ferroni C, Pepe A, Kim YS, Lee S, Guerrini A, Parenti MD, Tesei A, Zamagni A, Cortesi M, Zaffaroni N, De Cesare M, Beretta GL, Trepel JB, Malhotra SV, Varchi G. 1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment. J Med Chem 2017; 60:3082-3093. [PMID: 28272894 DOI: 10.1021/acs.jmedchem.7b00105] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Prostate cancer (PC) is the fifth leading cause of cancer death in men, and the androgen receptor (AR) represents the primary target for PC treatment, even though the disease frequently progresses toward androgen-independent forms. Most of the commercially available nonsteroidal antiandrogens show a common scaffold consisting of two aromatic rings connected by a linear or a cyclic spacer. By taking advantage of a facile, one-pot click chemistry reaction, we report herein the preparation of a small library of novel 1,4-substituted triazoles with AR antagonistic activity. Biological and theoretical evaluation demonstrated that the introduction of the triazole core in the scaffold of nonsteroidal antiandrogens allowed the development of small molecules with improved overall AR-antagonist activity. In fact, compound 14d displayed promising in vitro antitumor activity toward three different prostate cancer cell lines and was able to induce 60% tumor growth inhibition of the CW22Rv1 in vivo xenograft model. These results represent a step toward the development of novel and improved AR antagonists.
Collapse
Affiliation(s)
- Claudia Ferroni
- Institute for the Organic Synthesis and Photoreactivity, Italian National Research Council , Via Gobetti 101, 40129 Bologna, Italy
| | - Antonella Pepe
- Purdue Center for Cancer Research , 720 Clinic Drive, West Lafayette, Indiana 47907, United States
| | - Yeong Sang Kim
- Center for Cancer Research, National Cancer Institute, National Institutes of Health , Building 10, Magnuson CC, Bethesda, Maryland 20892, United States
| | - Sunmin Lee
- Center for Cancer Research, National Cancer Institute, National Institutes of Health , Building 10, Magnuson CC, Bethesda, Maryland 20892, United States
| | - Andrea Guerrini
- Institute for the Organic Synthesis and Photoreactivity, Italian National Research Council , Via Gobetti 101, 40129 Bologna, Italy
| | - Marco Daniele Parenti
- Institute for the Organic Synthesis and Photoreactivity, Italian National Research Council , Via Gobetti 101, 40129 Bologna, Italy
| | - Anna Tesei
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS , Via P. Maroncelli, 40, 47014 Meldola, Forlì Italy
| | - Alice Zamagni
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS , Via P. Maroncelli, 40, 47014 Meldola, Forlì Italy
| | - Michela Cortesi
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS , Via P. Maroncelli, 40, 47014 Meldola, Forlì Italy
| | - Nadia Zaffaroni
- Fondazione IRCCS Istituto Tumori Milano , Via Amadeo, 42, 20133 Milano, Italy
| | | | | | - Jane B Trepel
- Center for Cancer Research, National Cancer Institute, National Institutes of Health , Building 10, Magnuson CC, Bethesda, Maryland 20892, United States
| | - Sanjay V Malhotra
- Department of Radiation Oncology, Division of Radiation and Cancer Biology, Stanford University School of Medicine , Stanford, California 94304, United States
| | - Greta Varchi
- Institute for the Organic Synthesis and Photoreactivity, Italian National Research Council , Via Gobetti 101, 40129 Bologna, Italy
| |
Collapse
|
8
|
Enantioselective [4+2] cycloaddition reaction of α,β-unsaturated imine and methyl vinyl ketone catalyzed by chiral phosphine. Tetrahedron 2015. [DOI: 10.1016/j.tet.2015.04.076] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
9
|
Tian X, He Y, Zhou J. Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance. Front Pharmacol 2015; 6:57. [PMID: 25852559 PMCID: PMC4371693 DOI: 10.3389/fphar.2015.00057] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2014] [Accepted: 03/05/2015] [Indexed: 12/30/2022] Open
Abstract
Androgen receptor (AR) plays a critical role in the development and progression of prostate cancer (PCa). Current clinically used antiandrogens such as flutamide, bicalutamide, and newly approved enzalutamide mainly target the hormone binding pocket (HBP) of AR. However, over time, drug resistance invariably develops and switches these antiandrogens from antagonist to agonist of the AR. Accumulated evidence indicates that AR mutation is an important cause for the drug resistance. This review will give an overview of the mutation based resistance of the current clinically used antiandrogens and the rational drug design to overcome the resistance, provides a promising strategy for the development of the new generation of antiandrogens targeting HBP.
Collapse
Affiliation(s)
- Xiaohong Tian
- Lady Davis Institute, Jewish General Hospital, Mcgill University Montreal, QC, Canada
| | - Yang He
- Immunology, Institute of Medicinal Biotechnology Chinese Academy of Medical Science Beijing, China
| | - Jinming Zhou
- Immunology, Institute of Medicinal Biotechnology Chinese Academy of Medical Science Beijing, China
| |
Collapse
|
10
|
Quintard A, Cheshmedzhieva D, Sanchez Duque MDM, Gaudel-Siri A, Naubron JV, Génisson Y, Plaquevent JC, Bugaut X, Rodriguez J, Constantieux T. Origin of the enantioselectivity in organocatalytic Michael additions of β-ketoamides to α,β-unsaturated carbonyls: a combined experimental, spectroscopic and theoretical study. Chemistry 2014; 21:778-90. [PMID: 25382666 DOI: 10.1002/chem.201404481] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2014] [Revised: 09/18/2014] [Indexed: 12/27/2022]
Abstract
The organocatalytic enantioselective conjugate addition of secondary β-ketoamides to α,β-unsaturated carbonyl compounds is reported. Use of bifunctional Takemoto's thiourea catalyst allows enantiocontrol of the reaction leading either to simple Michael adducts or spirocyclic aminals in up to 99 % ee. The origin of the enantioselectivity has been rationalised based on combined DFT calculations and kinetic analysis. This study provides a deeper understanding of the reaction mechanism, which involves a predominant role of the secondary amide proton, and clarifies the complex interactions occurring between substrates and the catalyst.
Collapse
Affiliation(s)
- Adrien Quintard
- Aix Marseille Université, Centrale Marseille, CNRS, iSm2 UMR 7313, 13397, Marseille (France). Fax: (+33) 491-289-187
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Guerrini A, Tesei A, Ferroni C, Paganelli G, Zamagni A, Carloni S, Di Donato M, Castoria G, Leonetti C, Porru M, De Cesare M, Zaffaroni N, Beretta GL, Del Rio A, Varchi G. A New Avenue toward Androgen Receptor Pan-antagonists: C2 Sterically Hindered Substitution of Hydroxy-propanamides. J Med Chem 2014; 57:7263-79. [DOI: 10.1021/jm5005122] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- Andrea Guerrini
- Institute
for the Organic Synthesis and Photoreactivity, Italian National Research Council, Via Gobetti 101, 40129 Bologna, Italy
| | - Anna Tesei
- I.R.S.T., Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Via P. Maroncelli, 40, 47014 Meldola, Forlì, Italy
| | - Claudia Ferroni
- Institute
for the Organic Synthesis and Photoreactivity, Italian National Research Council, Via Gobetti 101, 40129 Bologna, Italy
| | - Giulia Paganelli
- I.R.S.T., Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Via P. Maroncelli, 40, 47014 Meldola, Forlì, Italy
| | - Alice Zamagni
- I.R.S.T., Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Via P. Maroncelli, 40, 47014 Meldola, Forlì, Italy
| | - Silvia Carloni
- I.R.S.T., Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Via P. Maroncelli, 40, 47014 Meldola, Forlì, Italy
| | - Marzia Di Donato
- Department
of Biochemistry, Biophysics and General Pathology, II University of Naples, Via L. De Crecchio, 7, 80138 Naples, Italy
| | - Gabriella Castoria
- Department
of Biochemistry, Biophysics and General Pathology, II University of Naples, Via L. De Crecchio, 7, 80138 Naples, Italy
| | - Carlo Leonetti
- Experimental
Chemotherapy Laboratory, Regina Elena National Cancer Institute, Via
delle Messi d’Oro, 156, 00158 Rome, Italy
| | - Manuela Porru
- Experimental
Chemotherapy Laboratory, Regina Elena National Cancer Institute, Via
delle Messi d’Oro, 156, 00158 Rome, Italy
| | - Michelandrea De Cesare
- Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Via Amadeo, 42, 20133 Milano, Italy
| | - Nadia Zaffaroni
- Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Via Amadeo, 42, 20133 Milano, Italy
| | - Giovanni Luca Beretta
- Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Via Amadeo, 42, 20133 Milano, Italy
| | - Alberto Del Rio
- Institute
for the Organic Synthesis and Photoreactivity, Italian National Research Council, Via Gobetti 101, 40129 Bologna, Italy
| | - Greta Varchi
- Institute
for the Organic Synthesis and Photoreactivity, Italian National Research Council, Via Gobetti 101, 40129 Bologna, Italy
| |
Collapse
|
12
|
Jin W, Wong WT, Law GL. A Simple and Direct Method for the Palladium-Catalyzed Oxidative Coupling of Unactivated Allylarenes with Classic Arenes. ChemCatChem 2014. [DOI: 10.1002/cctc.201402075] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
13
|
Kim YW, Georg GI. Boron-Heck reaction of cyclic enaminones: regioselective direct arylation via oxidative palladium(II) catalysis. Org Lett 2014; 16:1574-7. [PMID: 24650204 PMCID: PMC3993847 DOI: 10.1021/ol500105d] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
An oxidative boron-Heck reaction of cyclic enaminones with arylboronic acids is reported. This protocol provides a regioselective arylation at the C6 position of cyclic enaminones. When an N-carbamylated cyclic enaminone was employed, a switch to a conjugate addition reaction occurred in the presence of acid.
Collapse
Affiliation(s)
- Yong Wook Kim
- Department of Chemistry, Department of Medicinal Chemistry, and the Institute for Therapeutic Discovery and Development, University of Minnesota , 717 Delaware Street SE, Minneapolis, Minnesota 55414, United States
| | | |
Collapse
|